

# Resource Summary Report

Generated by [dkNET](#) on Aug 29, 2026

## Pim-2 (D1D2) XP Rabbit mAb

RRID:AB\_2163921

Type: Antibody

---

### Proper Citation

Cell Signaling Technology Cat# 4730, RRID:AB\_2163921

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2163921](http://antibodyregistry.org/AB_2163921)

**Proper Citation:** Cell Signaling Technology Cat# 4730, RRID:AB\_2163921

**Target Antigen:** PIM2

**Host Organism:** rabbit

**Clonality:** monoclonal

**Comments:** Applications: W, IP. Consolidation on 10/2018: AB\_10342446, AB\_10860593, AB\_2163921.

**Antibody Name:** Pim-2 (D1D2) XP Rabbit mAb

**Description:** This monoclonal targets PIM2

**Target Organism:** human

**Antibody ID:** AB\_2163921

**Vendor:** Cell Signaling Technology

**Catalog Number:** 4730

**Record Creation Time:** 20250820T002849+0000

**Record Last Update:** 20250820T082316+0000

---

### Ratings and Alerts

No rating or validation information has been found for Pim-2 (D1D2) XP Rabbit mAb.

No alerts have been found for Pim-2 (D1D2) XP Rabbit mAb.

## Data and Source Information

**Source:** [Antibody Registry](#)

## Usage and Citation Metrics

We found 4 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Torres-Ayuso P, et al. (2024) PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer. *Cell chemical biology*, 31(2), 326.

Buchacher T, et al. (2023) PIM kinases regulate early human Th17 cell differentiation. *Cell reports*, 42(12), 113469.

Kunder R, et al. (2022) Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. *Cell chemical biology*, 29(3), 358.

Bearss JJ, et al. (2021) EDC3 phosphorylation regulates growth and invasion through controlling P-body formation and dynamics. *EMBO reports*, 22(4), e50835.